The abstract is read at the publisher; the summary is JClub's.
NFV combined with cisplatin in ovarian cancer cells enhances cytoplasmic DNA sensing and inflammatory signaling, yielding protective vaccination against live ID8 challenge in mice.
- Why it matters: Platinum resistance and weak responses to immune checkpoint inhibitors leave a need to improve how cisplatin kills tumors in an immunogenic way.
- What they did: RNA-seq and biochemical assays showed NFV-containing treatments enriched interferon and antigen presentation pathways, increased extranuclear double-stranded DNA and cytosolic TP53 DNA, and boosted STING and TBK1 phosphorylation.
- The result: The combination increased ICD-associated mediators (HMGB1, IL18, IFNbeta) and, when used to vaccinate immunocompetent female mice, reduced tumor incidence and burden versus freeze-thaw necrosis controls.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.